Overview
Michael Atkins is an Oncologist in Washington, Washington, D.c.. Dr. Atkins has been practicing medicine for over 42 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Wilms Tumor, Familial Wilms Tumor 2, Renal Cell Carcinoma (RCC), and Clear Cell Sarcoma.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- HMO
- PPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
Locations
3800 Reservoir Rd Nw, Washington, DC 20007
Inova Health Care Services
Jeanny Aragon-Ching is an Oncologist and a Hematologist in Alexandria, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.
University Of Maryland Oncology Associates PA
Heather Mannuel is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mannuel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Prostate Cancer, and Renal Cell Carcinoma (RCC). Dr. Mannuel is currently accepting new patients.
Skip Viragh Outpatient Cancer Center
Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chromophobe Renal Cell CarcinomaDr. Atkins isDistinguished. Learn about Chromophobe Renal Cell Carcinoma.
- Clear Cell SarcomaDr. Atkins isDistinguished. Learn about Clear Cell Sarcoma.
- Familial Wilms Tumor 2Dr. Atkins isDistinguished. Learn about Familial Wilms Tumor 2.
- Renal Cell Carcinoma (RCC)Dr. Atkins isDistinguished. Learn about Renal Cell Carcinoma (RCC).
- Wilms TumorDr. Atkins isDistinguished. Learn about Wilms Tumor.
- WT1-Related Wilms Tumor SyndromesDr. Atkins isDistinguished. Learn about WT1-Related Wilms Tumor Syndromes.
- Advanced
- Adult Soft Tissue SarcomaDr. Atkins isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- MelanomaDr. Atkins isAdvanced. Learn about Melanoma.
- Experienced
- Melanoma of the EyeDr. Atkins isExperienced. Learn about Melanoma of the Eye.
- Metastatic Brain TumorDr. Atkins isExperienced. Learn about Metastatic Brain Tumor.
- Posterior Fossa TumorDr. Atkins isExperienced. Learn about Posterior Fossa Tumor.
- Primitive Neuroectodermal Tumor (PNET)Dr. Atkins isExperienced. Learn about Primitive Neuroectodermal Tumor (PNET).
- Pseudomyxoma PeritoneiDr. Atkins isExperienced. Learn about Pseudomyxoma Peritonei.
